Table 1 Clinical data of 8 patients diagnosed as combined hepatocellular-cholangiocarcinoma with stem cell feature
Case | Age at surgery | Sex | Etiology | Liver fibrosis (Ishak stage 0–6) | Serum AFP (µg/L) | Serum CA19-9 (µg/L) | Tumor location (segments) | Tumor number | Maxi tumor diameter (cm) | Diagnosis according to WHO criteria | Minor component within intermediated areas | Prognosis |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 50 | M | HBV | 6 | 51.2 | 27.2 | IV, V | 1 | 2 | CHC with stem cell feature, typical type, | Intermediate-cell foci | Lost follow-up |
2 | 64 | M | HBV | 2 | 7.6 | N/A | VI, VII | 1 | 10 | CHC with stem cell feature, intermediate cell type | None | Recurrence was diagnosed by CT scan in liver at 11 mos. Patient died at 14 mos |
3 | 49 | M | HBV | 6 | > 1000.0 | 0 | VIII | 1 | 6.5 | CHC with stem cell feature, intermediate cell type | Cholangiolocellular foci | Recurrence in liver was diagnosed by CT scan at 13 mos. Patient died soon after recurrence |
4 | 52 | M | HBV | 3 | 61.2 | 0.1 | V | 1 | 2 | CHC with stem cell feature, intermediate cell type | Foci with typical type appearance | None recurrence was found at 74 mos |
5 | 39 | M | HBV | 6 | > 1000.0 | 26.2 | IV | 1 | 4.5 | CHC with stem cell feature, intermediate cell type | None | New tumor was diagnosed by CT and DSA in liver at 2 mos. patient received TACE, died at 5 mos |
6 | 55 | M | HBV | 6 | 561.5 | 17.5 | VI | 1 | 5.3 | CHC with stem cell feature, intermediate cell type | Foci with typical type appearance and cholangiolocellular foci | New tumor was diagnosed by CT at 42 mos. Patient then received repeat hepatectomy. Resected specimen was pathologically diagnosed as HCC. None recurrence was found at the time of follow-up closure |
7 | 42 | M | HCV | 6 | 95.1 | 39.9 | II, III, IV | 3 | 9.2 | CHC with stem cell feature, intermediate cell type | None | Patient died of hemorrhage with no evidence of recurrence at 4 mos |
8 | 53 | M | HBV | 6 | > 1000.0 | 31.8 | II, III, IV | 3 | 5.5 | CHC with stem cell feature, intermediate cell type | None | New tumor was diagnosed by CT and DSA in liver at 2 mos. After receiving TACE for several times, patient died at 23 mos |